Paricalcitol

Paricalcitol is a lipid of Sterol Lipids (ST) class. Paricalcitol is associated with abnormalities such as Vitamin D Deficiency. The involved functions are known as Hypertrophy, Left Ventricular. Paricalcitol often locates in Blood.

Cross Reference

Introduction

To understand associated biological information of Paricalcitol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Paricalcitol?

Paricalcitol is suspected in Vitamin D Deficiency and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

No disease MeSH terms mapped to the current reference collection.

PubChem Associated disorders and diseases

What pathways are associated with Paricalcitol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Paricalcitol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Paricalcitol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Paricalcitol?

There are no associated biomedical information in the current reference collection.

What genes are associated with Paricalcitol?

There are no associated biomedical information in the current reference collection.

What common seen animal models are associated with Paricalcitol?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Paricalcitol

Download all related citations
Per page 10 20 50 100 | Total 375
Authors Title Published Journal PubMed Link
Chen S and Gardner DG Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. 2013 J. Steroid Biochem. Mol. Biol. pmid:22989481
El-Khoury JM et al. Does Paricalcitol (Zemplar®) interfere with 1,25-dihydroxyvitamin D measurement by liquid chromatography-tandem mass spectrometry assays? 2013 Clin. Chim. Acta pmid:23142648
Moe SM and Thadhani R What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? 2013 Curr. Opin. Nephrol. Hypertens. pmid:24100218
Havakuk O et al. Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model. 2013 Isr. Med. Assoc. J. pmid:24511650
de Boer IH et al. Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. 2013 Kidney Int. pmid:22913981
Nigwekar SU and Thadhani RI Shining light on vitamin D trials in chronic kidney disease. 2013 Kidney Int. pmid:23364588
Sánchez-Álvarez JE et al. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. 2013 Nefrologia pmid:23364628
Wu-Wong JR et al. Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats. 2013 Life Sci. pmid:23261531
Hwang HS et al. Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. 2013 Nephrol. Dial. Transplant. pmid:23229926
Ong LM et al. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. 2013 Nephrology (Carlton) pmid:23311404